Establishing the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study.

Establishing the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study.

May 29, 2020 Leave a comment
Community-based research has gained increasing recognition in health research over the last two decades. Such participatory research approaches are lauded for their ability to anchor research in lived experiences, ensuring cultural appropriateness, accessing local knowledge, reaching marginalized communities, building capacity, and facilitating research-to-action.
While having these positive attributes, the community-based health research literature is predominantly composed of small projects, using qualitative methods, and set within geographically limited communities. Its use in larger health studies, including clinical trials and cohorts, is limited. We present the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS), a large-scale, multi-site, national, longitudinal quantitative study that has operationalized community-based research in all steps of the research process. Successes, challenges and further considerations are offered.
Through the integration of community-based research principles, we have been successful in: facilitating a two-year long formative phase for this study; developing a novel survey instrument with national involvement; training 39 Peer Research Associates (PRAs); offering ongoing comprehensive support to PRAs; and engaging in an ongoing iterative community-based research process.
Our community-based research approach within CHIWOS demanded that we be cognizant of challenges managing a large national team, inherent power imbalances and challenges with communication, compensation and volunteering considerations, and extensive delays in institutional processes. It is important to consider the iterative nature of community-based research and to work through tensions that emerge given the diverse perspectives of numerous team members.
Community-based research, as an approach to large-scale quantitative health research projects, is an increasingly viable methodological option. Community-based research has several advantages that go hand-in-hand with its obstacles. We offer guidance on implementing this approach, such that the process can be better planned and result in success.
Establishing the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study.
Establishing the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study.

Status of vaccine research and development of vaccines for HIV-1.

Human immunodeficiency virus (HIV) is the cause of one of the most lethal pandemics in human history, although in recent years access to highly effective anti-retroviral therapy has provided new hope worldwide. Transmission of HIV by sexual contact, childbirth and injection drug use has been reduced, but 2 million are newly infected each year, and much of the transmission is from people who do not know their status. In addition to known methods, a preventive vaccine is needed to end the pandemic.

Nitroblue tetrazolium chloride
GC4263-5G Glentham Life Sciences 5 g 265.2 EUR

Tetrazolium Red
HY-D0714 MedChemExpress 500mg 129.6 EUR

Tetrazolium Violet
GT6818-10G Glentham Life Sciences 10 g 351.6 EUR

Tetrazolium Violet
GT6818-1G Glentham Life Sciences 1 g 84 EUR

Tetrazolium Violet
GT6818-5G Glentham Life Sciences 5 g 204 EUR

Tetranitroblue tetrazolium chloride
GK5496-100MG Glentham Life Sciences 100 mg 76.8 EUR

Tetranitroblue tetrazolium chloride
GK5496-1G Glentham Life Sciences 1 g 284.4 EUR

Tetrazolium Blue Chloride
GT7170-1G Glentham Life Sciences 1 g 84 EUR

Tetrazolium Blue Chloride
GT7170-5G Glentham Life Sciences 5 g 180 EUR

Thiazolyl Blue Tetrazolium Bromide
20-abx082213 Abbexa
  • 243.60 EUR
  • 385.20 EUR
  • 250 mg
  • 5 g

Thiazolyl Blue Tetrazolium Bromide
20-abx082549 Abbexa
  • 226.80 EUR
  • 326.40 EUR
  • 250 mg
  • 5 g

Thiazolyl Blue Tetrazolium Bromide
abx188911-50g Abbexa 50 g 927.6 EUR

Thiazolyl blue tetrazolium bromide
GC4568-10G Glentham Life Sciences 10 g 208.8 EUR

Thiazolyl blue tetrazolium bromide
GC4568-1G Glentham Life Sciences 1 g 74.4 EUR

Thiazolyl blue tetrazolium bromide
GC4568-5G Glentham Life Sciences 5 g 132 EUR

Nitro blue tetrazolium chloride
HY-15925 MedChemExpress 250mg 142.8 EUR

Tetranitroblue tetrazolium chloride (TNBT)
T6756 Bio Basic 250mg 99.67 EUR

NBT (nitro blue tetrazolium, chloride)
10008 Biotium 250MG 109.2 EUR
Description: Minimum order quantity: 1 unit of 250MG

NBT (nitro blue tetrazolium, chloride)
10008-1 Biotium 1G 213.6 EUR
Description: Minimum order quantity: 1 unit of 1G

NBT (nitro blue tetrazolium, chloride)
10008-2 Biotium 5G 663.6 EUR
Description: Minimum order quantity: 1 unit of 5G

Nitro blue tetrazolium chloride monohydrate
20-abx184281 Abbexa
  • 292.80 EUR
  • 526.80 EUR
  • 1 g
  • 5 g

Thiazolyl blue tetrazolium bromide (MTT)
T0793 Bio Basic 500mg 86.1 EUR

CTC (5-Cyano-2, 3-ditolyl tetrazolium chloride)
10063 Biotium 10MG 121.2 EUR
Description: Minimum order quantity: 1 unit of 10MG

The extraordinary mutability and genetic diversity of HIV is an enormous challenge, but vaccines are being designed for broad coverage. Computer-aided design of mosaic immunogens, incorporating many epitopes from the entire genome or from conserved regions aim to induce CD8+ T cells to kill virus-infected cells or inhibit virus replication, while trimeric envelope proteins or synthetic mimics aim to induce broadly reactive neutralizing antibodies similar to those cloned from some infected patients.

Induction of more potent and durable responses may require new adjuvants or replicating chimeric vectors chimeras that bear HIV genes. Passive or genetic delivery of broadly neutralizing antibodies may provide broad protection and/or lead to insights for vaccine designers. Proof-of-concept trials in non-human primates and in one human efficacy trial have provided scientific clues for a vaccine that could provide broad and durable protection against HIV. The use of vaccines to destroy HIV reservoirs as part of therapy or cure is now also being explored.

Leave a Reply

Your email address will not be published.